Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Exclusion Criteria

• •(1) Malignant tumors other than acute myeloid leukemia within 5 years before screening;
• •(2) Those who test positive for virus and syphilis;
• •(3) Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association \[NYHA\] classification≥ grade III), severe arrhythmia;
• •(4) Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment;
• •(5) Active infection or uncontrollable infection requiring systemic treatment within 7 days prior to screening;
• •(6) pregnant or lactating women, female subjects who planned to become pregnant within 2 years after cell reinfusion or male subjects whose partners planned to become pregnant within 2 years after their cell reinfusion;
• •(7) Subjects who were receiving systemic steroid therapy within 7 days prior to the year or who were judged by the investigator to require long-term systemic steroid therapy during treatment (other than inhalation or topical use);
• •(8) Have participated in other clinical studies within 1 month before screening;
• •(9) There was evidence of central nervous system invasion during subject screening, such as tumor cells detected in cerebrospinal fluid or imaging showing central infiltration;
• •(10) Those who have graft-versus-host response and need to use immunosuppressants;
• •(11) Those with a history of epilepsy or other central nervous system diseases;
• •(12) Patients with primary immunodeficiency diseases;
• •(13) situations that other investigators consider unsuitable for enrollment.